Bempify 180mg Tablet is a prescription lipid-lowering medicine containing bempedoic acid 180mg. It belongs to a class of medicines known as adenosine triphosphate-citrate lyase (ACL) inhibitors and is used to help reduce elevated low-density lipoprotein cholesterol (LDL-C) in appropriate adults. Indian medicine listings identify Bempify 180mg as a Lupin product containing bempedoic acid 180mg.
Bempedoic acid may be used as part of a cholesterol-management plan that includes diet, exercise and other LDL-lowering therapy, depending on the patient's clinical needs and tolerance of other medicines. Current FDA labeling includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), either with other LDL-C-lowering therapies or alone when concomitant LDL-lowering therapy is not possible.
Bempedoic acid works by inhibiting ATP-citrate lyase (ACL), an enzyme involved in cholesterol synthesis in the liver. ACL acts upstream of HMG-CoA reductase in the cholesterol-production pathway. Blocking this pathway reduces hepatic cholesterol synthesis and promotes changes that lower circulating LDL cholesterol.
Bempify 180mg should be taken exactly as prescribed by a healthcare professional. Current bempedoic-acid labeling uses a dose of 180mg orally once daily, with or without food. The tablet should be taken consistently and should not be stopped simply because high cholesterol usually causes no noticeable symptoms.
An important safety consideration with bempedoic acid is increased uric acid (hyperuricemia), which can trigger or worsen gout in susceptible patients. Current labeling recommends monitoring uric acid when clinically appropriate.
Bempedoic acid has also been associated with tendon injury or tendon rupture. Patients should seek medical advice for sudden tendon pain, swelling or difficulty moving a joint, particularly if they have a history of tendon problems.
Commonly reported adverse reactions include hyperuricemia, muscle spasms, back pain, abdominal discomfort, pain in the extremities, anemia and elevated liver enzymes. In cardiovascular-outcomes studies, gout, renal-function changes and gallstones were also reported more often with bempedoic acid than placebo.
Patients should inform their prescriber about all other cholesterol medicines. Current FDA labeling specifically advises avoiding bempedoic acid with simvastatin doses above 20mg or pravastatin doses above 40mg because bempedoic acid can increase statin exposure and the risk of muscle-related adverse effects.
Product Information
Brand Name: Bempify 180mg Tablet
Generic Name: Bempedoic Acid
Strength: 180 mg
Dosage Form: Tablet
Route: Oral
Drug Class: ATP-Citrate Lyase (ACL) Inhibitor / Lipid-Lowering Agent
Primary Use: Reduction of elevated LDL cholesterol
Relevant Conditions: Hypercholesterolemia, including HeFH, depending on local prescribing indications
Marketer: Lupin Ltd
Prescription Status: Prescription medicine